Form 4: Corcept Therapeutics Director, David Mahoney, Acquires 30,000 Stock Options
SEC Form 4 Filing
David Mahoney, a director of Corcept Therapeutics, acquired 30,000 stock options on May 17, 2024.
Summary
- On May 17, 2024, David Mahoney, a director of Corcept Therapeutics, acquired 30,000 stock options.
- The exercise price of these options is $28.09.
- The options vest ratably in equal monthly installments over a one-year period, starting May 17, 2024.
- The options expire on May 16, 2034.
- Following the transaction, Mahoney directly owns 30,000 derivative securities.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing, indicating a neutral sentiment. It simply reports the acquisition of stock options by a company director.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, providing transparency to the market regarding the actions of company directors. It is common for directors to receive stock options as part of their compensation.
Stakeholder Impact
- The acquisition of stock options by a director could be perceived positively by shareholders, as it aligns the director's interests with the company's long-term success.
Key Dates
| Date | Description |
|---|---|
| 05/17/2024 | Date of transaction: David Mahoney acquired 30,000 stock options; options begin to vest monthly over one year. |
| 05/16/2034 | Expiration date of the stock options. |
| 05/21/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.